161 related articles for article (PubMed ID: 6664381)
1. Involvement of central dopamine receptors in the hypotensive action of pergolide.
Jadhav AL; Willett RN; Sapru HN; Lokhandwala MF
Naunyn Schmiedebergs Arch Pharmacol; 1983 Dec; 324(4):281-6. PubMed ID: 6664381
[TBL] [Abstract][Full Text] [Related]
2. Effects of pergolide, a dopamine receptor agonist, and clonidine on cardiovascular responses evoked by activation of peripheral sympathetic outflow in rats.
Cavero I
Clin Exp Hypertens A; 1982; 4(1-2):221-33. PubMed ID: 7074987
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.
Cavero I; Lorrain J; Di Paola ED; Lhoste F; Payen B; Dennis T; Scatton B
J Pharmacol Exp Ther; 1985 Dec; 235(3):798-809. PubMed ID: 2934543
[TBL] [Abstract][Full Text] [Related]
4. Central and peripheral dopaminergic mechanisms in the cardiovascular actions of pergolide in neurogenic hypertensive dogs.
Barrett RJ; Lokhandwala MF
Eur J Pharmacol; 1983 Dec; 96(3-4):211-26. PubMed ID: 6676105
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.
Cavero I; Lefevre-Borg F; Lhoste F; Sabatier C; Richer C; Giudicelli JF
J Pharmacol Exp Ther; 1984 Mar; 228(3):779-91. PubMed ID: 6707926
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the neurogenic vasodilatation elicited by central dopamine receptor stimulation with pergolide.
Lokhandwala MF; Kivlighn SD; Jandhyala BS
J Pharmacol Exp Ther; 1984 Mar; 228(3):696-703. PubMed ID: 6707919
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic inhibition of cardiac sympathetic nerve function by pergolide.
Barrett RJ; Lokhandwala MF
Eur J Pharmacol; 1982 Jan; 77(1):79-83. PubMed ID: 6277657
[TBL] [Abstract][Full Text] [Related]
8. Selective activation by LY-141865 and apomorphine of presynaptic dopamine receptors in the rat kidney and influence of stimulation parameters in the action of dopamine.
Lokhandwala MF; Steenberg ML
J Pharmacol Exp Ther; 1984 Jan; 228(1):161-7. PubMed ID: 6694099
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular characterization of the DA2 dopamine receptor agonist quinpirole in rats.
Lefevre-Borg F; Lorrain J; Lechaire J; Thiry C; Lhoste F; Hicks PE; Cavero I
Fundam Clin Pharmacol; 1987; 1(3):179-200. PubMed ID: 2892767
[TBL] [Abstract][Full Text] [Related]
10. The role of central dopamine (DA) receptors in the regulation of blood pressure.
Jaszlits L; Tardos L; Borsy J
Pol J Pharmacol Pharm; 1985; 37(3):405-10. PubMed ID: 4070082
[TBL] [Abstract][Full Text] [Related]
11. B-HT 958 lowers blood pressure and heart rate in the rat through stimulation of dopamine receptors.
Brown MJ; Harland D
Br J Pharmacol; 1986 Feb; 87(2):361-70. PubMed ID: 3006858
[TBL] [Abstract][Full Text] [Related]
12. Presynaptic dopamine receptor stimulation in the cardiovascular actions of lergotrile.
Barrett RJ; Lokhandwala MF
J Pharmacol Exp Ther; 1981 Jun; 217(3):660-5. PubMed ID: 6112262
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the hypotensive action of dopamine receptor agonists fenoldopam and quinpirole in anaesthetized rats.
Sengupta S; Lokhandwala MF
J Auton Pharmacol; 1985 Dec; 5(4):289-94. PubMed ID: 2869041
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological analysis of the actions of SKF 82526 on cardiovascular dopamine receptors.
Lokhandwala MF; Watkins HO; Sabouni MH; Alkadhi KA
J Pharmacol Exp Ther; 1985 Aug; 234(2):337-44. PubMed ID: 2862275
[TBL] [Abstract][Full Text] [Related]
15. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists.
Fuller RW; Snoddy HD
Neuropharmacology; 1984 Dec; 23(12A):1389-94. PubMed ID: 6527743
[TBL] [Abstract][Full Text] [Related]
16. Hypotensive action and alpha-adrenolytic properties of a new dopaminergic agonist, CU 32-085, in the rat.
Morales-Olivas FJ; Palop V; Rubio E; Esplugues J
Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):71-8. PubMed ID: 6151381
[TBL] [Abstract][Full Text] [Related]
17. Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone.
Cavero I; Lefèvre-Borg F; Gomeni R
J Pharmacol Exp Ther; 1981 Aug; 218(2):515-24. PubMed ID: 7252851
[TBL] [Abstract][Full Text] [Related]
18. Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part II: Sites and mechanisms of action of dopamine receptor agonists.
Cavero I; Massingham R; Lefèvere-Borg F
Life Sci; 1982 Sep; 31(11):1059-69. PubMed ID: 6755118
[TBL] [Abstract][Full Text] [Related]
19. Involvement of peripheral dopamine receptors in the antihypertensive effect of a new ergoline derivative (355/1057).
Salvati P; Bianchi G
Arch Int Pharmacodyn Ther; 1985 Apr; 274(2):291-304. PubMed ID: 4026460
[TBL] [Abstract][Full Text] [Related]
20. Identification of dopamine receptor subtypes in the hypotensive action of SK&F 85174 in anesthetized rats.
Sowinski BA; Lokhandwala MF
J Auton Pharmacol; 1987 Jun; 7(2):105-9. PubMed ID: 2888767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
